93 related articles for article (PubMed ID: 16787685)
1. Synchronous multiple primary lung cancers with different response to gefitinib.
Ryoo BY; Na II; Yang SH; Koh JS; Kim CH; Lee JC
Lung Cancer; 2006 Aug; 53(2):245-8. PubMed ID: 16787685
[TBL] [Abstract][Full Text] [Related]
2. Synchronous double primary lung cancers with different response to pemetrexed.
Umemura S; Yamane H; Yano T; Hoshika T; Shiote Y; Takigawa N; Suwaki T; Shirakawa A; Kamei H
Anticancer Drugs; 2011 Jun; 22(5):473-6. PubMed ID: 21346552
[TBL] [Abstract][Full Text] [Related]
3. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
4. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
[TBL] [Abstract][Full Text] [Related]
6. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
[TBL] [Abstract][Full Text] [Related]
7. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
8. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
9. Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
Zhang D; Takigawa N; Ochi N; Tanimoto Y; Noujima D; Chen YY; Tanimoto M; Kiura K
Lung Cancer; 2011 Sep; 73(3):379-80. PubMed ID: 21684624
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
11. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.
Zhong WZ; Wu YL; Yang XN; Guo AL; Su J; Zhang XC; Luo DL; Wang Z; Chen HJ; Zhou Q; Xu CR; Qiao GB; Liao RQ; Yang JJ; Mok TS
Clin Lung Cancer; 2010 May; 11(3):160-8. PubMed ID: 20439191
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
15. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
Haneda H; Sasaki H; Lindeman N; Kawano O; Endo K; Suzuki E; Shimizu S; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Feb; 36(2):69-75. PubMed ID: 16449241
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Kozuki T; Hisamoto A; Tabata M; Takigawa N; Kiura K; Segawa Y; Nakata M; Mandai K; Eguchi K; Ueoka H; Tanimoto M
Lung Cancer; 2007 Oct; 58(1):30-5. PubMed ID: 17561305
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
